Bempegaldesleukin Plus Nivolumab Elicits Responses in Treatment-Naïve, Advanced Melanoma
More than half of patients responded, and responses deepened over time.
Melanoma
Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival
Immune-related adverse events were associated with improved survival outcomes.
Melanoma Brain Metastases: ‘Absolutely Treatable in 2021’
Experts outline treatment options and make recommendations.
Study Supports Routine PET-CT Surveillance for Asymptomatic, High-Risk Melanoma
PET-CT results led to management changes in 15% of patients.
LEAP-004: Durable Responses in Advanced Melanoma Achieved With Lenvatinib Plus Pembrolizumab
In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
Neoadjuvant Nivolumab Plus Relatlimab Produced a High pCR Rate in Stage III-IV Melanoma
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Greater Benefit With Pembrolizumab in Crossover vs Rechallenged Patients With Cutaneous Melanoma
Patients were more likely to benefit from pembrolizumab if they had not previously received the drug.
Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk Melanoma
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
Lifileucel Could Be a New Standard of Care for Patients With Heavily Pretreated Metastatic Melanoma
Lifileucel has produced responses lasting more than 2 years in patients with limited treatment options.
New Checkpoint Inhibitor Relatlimab Works With Nivolumab to Improve PFS in Melanoma
This is the first phase 3 study to validate LAG-3 inhibition as a therapeutic strategy in cancer, according to an investigator.
- Loading...
Loading...
Next post in ASCO 2021
Loading... 
Loading...